慢性心力衰竭与肌少症发病机制及治疗的研究进展  

Research progress in pathogenesis and treatment of chronic heart failure and sarcopenia

作　　者：刘婷婷[1] 刘海霞 周萍[1] LIU Ting-ting;LIU Hai-xia;ZHOU Ping(Department of Geriatrics,Second Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150081,China)

机构地区：[1]哈尔滨医科大学附属第二医院老年病科,黑龙江哈尔滨150081 [2]上海市第四人民医院老年病科

出　　处：《心血管康复医学杂志》2024年第2期256-259,共4页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：肌少症是一种与增龄相关的老年综合征,其特征是肌肉质量、力量和躯体功能的逐渐减退。慢性心力衰竭(Chronic heart failure,CHF)是各种心血管疾病的最终阶段。CHF是心脏衰老的主要发病机制,并可能发展为心脏恶病质。此外,CHF可引起多种代谢并发症,也可能导致肌少症。因此,肌少症可能作为与心衰相关的衰弱、残疾和死亡率的有力预测因子。本文的目的是对心力衰竭与肌少症的发病机制及治疗的最新进展作一综述。Sarcopenia is a geriatric syndrome associated with aging characterized by a gradual decline in muscle mass,strength,and physical function.Chronic heart failure(CHF)is the final stage of various cardiovascular diseases,which is the main pathogenesis of cardiac aging and may develop into cardiac cachexia.In addition,CHF can cause a variety of metabolic complications and may also lead to sarcopenia.Therefore,sarcopenia may be a strong predictor of frailty,disability and mortality associated with heart failure.The purpose of this article is to review the recent progress in the pathogenesis and treatment of heart failure and sarcopenia.

关 键 词：心力衰竭 肌减少症 治疗 

分 类 号：R541.6[医药卫生—心血管疾病]